Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caecal pH as a Biomarker in IBS
NCT02360384Unknown
- Sponsor
- Wingate Institute of Neurogastroenterology
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, single-blind trial of linaclotide in irritable bowel syndrome (IBS) (3 arms), sponsored by Wingate Institute of Neurogastroenterology. Primary endpoint: Change in pH around the ileocaecal valve at 28 days. Status: unknown.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02360384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360384.